Skip to main content
Log in

Rimonabant: A novel treatment for obesity and the metabolic syndrome

  • Clinical Trials Report
  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Klein S, Burke LE, Bray GA, et al.: Clinical implications of obesity with specific focus on cardiovascular disease: a statement for professionals from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation 2004, 110:2952–2967.

    Article  PubMed  Google Scholar 

  2. Bays HE: Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004, 12:1197–1211.

    Article  PubMed  CAS  Google Scholar 

  3. Cota D, Marsicano G, Tschop M, et al.: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003, 112:423–431.

    Article  PubMed  CAS  Google Scholar 

  4. Black SC: Cannabinoid receptor antagonists and obesity. Curr Opin Investig Drugs 2004, 5:389–394.

    PubMed  CAS  Google Scholar 

Download references

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Houri, M., Pratley, R.E. Rimonabant: A novel treatment for obesity and the metabolic syndrome. Curr Diab Rep 5, 43–44 (2005). https://doi.org/10.1007/s11892-005-0066-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-005-0066-4

Keywords

Navigation